Adaptimmune Therapeutics (ADAP) Earnings Date, Estimates & Call Transcripts $0.29 0.00 (-1.37%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Adaptimmune Therapeutics Earnings Summary Adaptimmune Therapeutics announced Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.18, which hit the consensus estimate of -$0.18. Quarterly revenue was reported to be $7.29 million, above the consensus estimate of $6.55 million. With a trailing EPS of -$0.27, Adaptimmune Therapeutics' earnings are expected to decrease next year, from ($0.14) to ($0.48) per share. Latest Q1 Earnings DateMay. 13EstimatedConsensus EPS (May. 13) -$0.18 Actual EPS (May. 13) -$0.18 Actual Revenue (May. 13) $7.29MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Adaptimmune Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataADAP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ADAP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Adaptimmune Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.23-$0.10-$0.17Q2 20253-$0.18-$0.03-$0.10Q3 20253-$0.10-$0.02-$0.06Q4 20253-$0.07-$0.01-$0.05 Adaptimmune Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025-$0.18-$0.18--$0.18$6.55M$7.29M3/24/2025Q4 2024-$0.17-$0.26 -$0.09-$0.29$16.56M$3.22M8/12/2024Q2 2024-$0.27+$0.27$0.27$58.00M$128.23M5/15/2024Q1 2024-$0.16-$0.18 -$0.02-$0.18$4.40M$5.68M3/6/2024Q4 2023-$0.12-$0.24 -$0.12-$0.24$4.80M$0.23M11/8/2023Q3 2023-$0.20-$0.20--$0.20$5.00M$7.32M8/9/2023Q2 2023-$0.17-$0.21 -$0.04-$0.30$5.00M$5.13M Adaptimmune Therapeutics Earnings - Frequently Asked Questions When did Adaptimmune Therapeutics announce their last quarterly earnings? Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earning data on Tuesday, May 13, 2025. Learn more on ADAP's earnings history. Did Adaptimmune Therapeutics beat their earnings estimates last quarter? In the previous quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) reported ($0.18) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.18). Learn more on analysts' earnings estimate vs. ADAP's actual earnings. How can I listen to Adaptimmune Therapeutics's earnings conference call? The conference call for Adaptimmune Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Adaptimmune Therapeutics's conference call transcript? The conference call transcript for Adaptimmune Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $178.03 million. How much profit does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$113.87 million. ADAP has generated -$0.27 earnings per share over the last four quarters. What is Adaptimmune Therapeutics's EPS forecast for next year? Adaptimmune Therapeutics's earnings are expected to decrease from ($0.14) per share to ($0.48) per share in the next year. More Earnings Resources from MarketBeat Related Companies ATYR Earnings ATAI Earnings ACB Earnings AQST Earnings CMPX Earnings DBVT Earnings CRVS Earnings RNAC Earnings AURA Earnings CGC Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:ADAP) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAP Stock Free ADAP Stock Alerts